This article was downloaded by: [The University of British Columbia] On: 11 October 2014, At: 03:55 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lncn19</u>

Cyclo-saligenyl-2',3'-dideoxy-2',3'didehydroythymidinemonophosphate (cycloSal-d4TMP) — A New Pro-Nucleotide Approach

Chris Meier a , Martina Lorey a , Eric De Clercq b & Jan Balzarini $_{b}$

^a Institute of Organic Chemistry, Johann Wolfgang Goethe-University, Marie-Curie-Str.11, D-60439, Frankfurt am Main, Germany

^b Rega Institute for Medical Research, Katholieke Universiteit Leuven , B-3000, Leuven, Belgium Published online: 16 Aug 2006.

To cite this article: Chris Meier , Martina Lorey , Eric De Clercq & Jan Balzarini (1997) Cyclo-saligenyl-2',3'-dideoxy-2',3'-didehydroythymidinemonophosphate (cycloSal-d4TMP) — A New Pro-Nucleotide Approach, Nucleosides and Nucleotides, 16:7-9, 1303-1306, DOI: 10.1080/07328319708006176

To link to this article: http://dx.doi.org/10.1080/07328319708006176

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms

& Conditions of access and use can be found at <u>http://www.tandfonline.com/page/</u> terms-and-conditions

CYCLO-SALIGENYL-2',3'-DIDEOXY-2',3'-DIDEHYDROYTHYMIDINEMONOPHOSPHATE (CYCLOSAL-D4TMP) - A NEW PRO-NUCLEOTIDE APPROACH -

Chris Meier^{a*}, Martina Lorey ^a, Eric De Clercq^b, and Jan Balzarini^b

a) Institute of Organic Chemistry, Johann Wolfgang Goethe-University, Marie-Curie-Str.11, D-60439 Frankfurt am Main, Germany

b) Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven,

Belgium

ABSTRACT: The synthesis of *cyclo*Sal-d4TMP 3a-g as new pro-nucleotide approach for d4TMP 2 is described. Phosphotriesters 3 release the d4TMP 2 selectively by a controlled, chemically induced tandem reaction. *Cyclo*Sal-phosphotriesters 3 exhibited high biological activity against HIV-1/HIV-2 in CEM cells which was completely retained in CEM TK⁻ cells.

2',3'-Dideoxy-2',3'-didehydrothymidine 1 (d4T, Stavudine, Cerit[®]) is used as antiviral agent in the treatment in AIDS. As compared to the anti-HIV drug AZT, d4T 1 shows comparable selective anti-HIV activity *in-vitro*. Moreover, d4T 1 has been found to be less toxic than AZT for bone marrow stem cells and to be less inhibitory to mitochondria DNA replication. After penetration through cell membranes, intracellular conversion of 1 into the 5'-triphosphate is essential for the expression of the biological activity, but the first thymidine kinase catalyzed phosphorylation into d4T-monophosphate 2 (d4TMP) is the limiting step of the metabolization in CEM and MT-4 cells. Consequently, the direct introduction of d4TMP 2 should bypass the limiting step and have advantages for the biological activity. Unfortunately, the highly polar monophosphate 2 is not able to penetrate membranes due to low lipophilicity. One attempt to improve the therapeutic potential of d4T 1 is the use of neutral, lipophilic prodrugs of d4TMP 2 (*Pro-Nucleotide-Approach*)¹.

Here we present the synthesis and properties of *cyclosal*igenyl **d4T**-monophosphate **3a-g** (*cycloSal-d4TMP*, scheme 1) as neutral prodrugs of d4TMP 2. This prodrug concept was designed to release the nucleotide 2 *selectively* by *controlled*, *chemically induced hydrolysis* according to a tandem-mechanism. In contrast to other reported prodrug concepts, our approach leads to d4TMP 2 after a *coupled* cleavage of the phenyl- and the benzylester bond of phosphotriesters of type 3. The rational of our new prodrug concept introduced here with 3 is based on the well known difference in stability of the phenyl- and

1303



3e: 5-Me, 3f: 3-Me, 3g: 3,5-di-Me

SCHEME 1: The hydrolysis pathways of cycloSal-d4TMP phosphotriesters 3

the benzyl phosphate ester that allows us to discriminate between the different phosphate ester bonds. The hydrolysis concept has already been verified and is summarized in scheme 1^2 . It involves a selective first cleavage of the phenolic ester bond to give 2-hydroxybenzylphosphodiester 4 (step a) and subsequently a spontaneously induced cleavage of 4 releasing d4TMP 2 and the salicylalcohols 5 (step b; tandem-reaction). Here we studied the effect of some more donor-substituted derivatives of the general structure 3.

The title compounds **3a-g** were synthesized as outlined in scheme 2. Salicylaldehydes **6** or salicylic acids **7** were used as starting materials, which were reduced by standard procedures to give the salicylalcohols **5** in 75-90% yield. Diols **5** were reacted with PCl₃ to yield the cyclic saligenylchlorophosphanes **8a-g** (50-85% yield). The *cyclo*Sal-d4TMP's **3a-g** were obtained from d4T **1** and 1.5 equiv. chlorophosphanes **8a-g** at O°C in the presence of di*-iso* propylethylamine (DIPEA) and subsequent *in-situ* oxidation with *t*-butylhydroperoxide. After purification (60-85% yield, 1:1 diastereomeric mixtures), the *cyclo*Sal-d4TMP's **3a-g** were characterized by means of ¹H, ¹³C, and ³¹P nmr, UV, and electrospray (ESI) mass spectrometry (negative mode). In the case of the 3,5-dimethyl derivative **3g**, we started from 2,4-dimethylphenol **9**, which was formylated using dichloromethylmethylether in the presence of TiCl₄ to give the appropriate salicylaldehyde **7g** in 86% yield (scheme 2).

The partition coefficients (PC values) of *cyclo*Sal-d4TMP's **3a-g** were determined in 1-octanol/phosphate buffer (pH 6.5) and are listed in table 1.

As a model for the physiological milieu, *cyclo*Sal-d4TMP's **3** were hydrolyzed in 30 mmol phosphate buffer, pH 7.29 at 37°C. In order to investigate the pH dependence of hydrolysis triesters **3a-g** were also studied in TRIS buffer (50 mmol, pH 6.8) and borate buffer (30 mmol, pH 8.9).

The hydrolyses were followed by means of HPLC analysis. Under the hydrolysis conditions at pH>7 all *cyclo*Sal-d4TMP's **3a-g** were degraded following pseudo-first order kinetics to give *only* d4TMP **2** and the salicylalcohols **5**. At pH<7, the 3,5-dimethyl-substituted derivative **3g** yielded also the "wrong" phenyl-d4T-phosphodiester in 30%. Furthermore, the expected pH dependence was observed. The half lives are summarized in



a) 5 equiv. TiCl₄, 3 equiv. Cl₂HCOCH₃, CH₂Cl₂, 0°C, 12 h, rt; b) NaBH₄ for 6 (LiAlH₄ for 7); c) PCl₃, pyridine, Et₂O, -10°C, 2 h; d) d4T 1, DIPEA, CH₃CN, 0°C, 20 min.; c) TBHP, CH₃CN, rt, 30 min.





FIGURE 1: Hydrolysis of *cyclo*Sal-d4TMP's **3a-g** in RPMI 1640 culture medium (A) and RPMI 1640 containing 10% heat-inactivated FCS (B)

table 1. All these results are in fully agreement with the designed hydrolysis pathway (scheme 1). Additionally, hydrolysis studies were carried out in RPMI culture medium with or without 10% heat-inactivated fetal calf serum (FCS). The products were identical as mentioned before (d4TMP 2 and diols 5a-g) but the half lives varied as can see in figure 1. Nevertheless, at least the strong donor substituted compounds 3d, 3e, 3f, and 3g showed half lives in FCS containing RPMI medium that should be high enough in order to serve as prodrug forms.

This assumption was verified by the evaluation of the antiviral activity of *cyclo*Sald4TMP's **3a-g** against HIV-1 and HIV-2 infected CEM/O cells and HIV-2 infected CEMthymidine kinase deficient (TK⁻) cells (table 1). The *cyclo*Sal-d4TMP's **3a**, **3b**, **3c**, and **3d**,

3a-g,	Hydrolysis (t _{1/2})			Antiviral Activity			PC value
d4T 1	in buffers			EC50 (µg/ml)			
	TRIS	phosphate	borate	CEM/O	CEM/O	CEM/TK-	
X	pH 6.9 [h]	pH 7.29 [h]	pH 8.9 [h]	HIV-1	HIV-2	HIV-2	
5-Cl	6.4	0.7	0.3	0.40	0.40	0.70	7.57
Н	24.5	4.5	1.1	0.25	1.20	1.20	1.90
5-OMe	28.3	7.2	1.07	0.60	0.70	0.70	2.30
3-OMe	9.5	1.4	0.4	0.70	0.60	4.00	0.83
5-Me	28.3	8.0	1.3	0.25	1.00	0.60	5.45
3-Me	68.5	10.2	1.5	0.10	0.25	0.25	5.08
3,5-Me	98.2	16.1	3.4	0.25	0.40	0.15	15.33
1				0.40	1.45	45	0.15

TABLE 1: Hydrolysis in different aqueous buffers, PC values, and antiviral activity of
cycloSal-d4TMP's 3

which have half live in RPMI/FCS medium up to 4.3h, showed at least equal activity in the wild type cell line as d4T 1 and (partly) a somewhat lower activity in the TK⁻ cell line. In contrast, all methyl-substituted triesters **3e-g** exhibited higher activity already in the CEM/O cell line as 1, which is completely *retained* in the TK⁻ cell line. This correlates with the higher stability of **3e-g** as compared to **3a-d** in the hydrolyses studies. No direct correlation of the antiviral activity with the lipophilicity of **3a-g** (PC values) was observed.

In summary, the described prodrug concept is suitable to deliver d4TMP 2 from *cyclo*Sal-d4TMP's **3a-g** by a non-enzymatical activation at physiological pH and donor-substituted derivatives of **3a-g** were highly active in CEM/TK⁻ cells. Further work is currently in progress in our laboratory in order to explore this *pro-nucleotide concept*.

REFERENCES

- Sergheraert, C.; Pierlot, C.; Tartar, A.; Henin, Y.; Lemaitre, M.; J. Med. Chem. 1993, 36, 826; Girardet, J.-L.; Perigaud, C.; Aubertin, A.-M.; Gosselin, G.; Kirn, A.; Imbach, J.-L.; Bioorg. Med. Chem. Lett. 1995, 5, 2981; McGuigan, C.; Cahard, D.; Sheeka, H.M.; De Clercq, E.; Balzarini, Bioorg. Med. Chem. Lett. 1996, 6, 1183.
- Meier, C.; Angew. Chem. 1996, 108, 77; Angew. Chem. Int. Ed. Engl. 1996, 35, 70; Meier, C; Lorey, M.; De Clercq, E.; Balzarini, J.; Antiviral Res. 1996, 28, A29.